Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 294.00
Bid: 292.00
Ask: 298.00
Change: -3.00 (-1.01%)
Spread: 6.00 (2.055%)
Open: 294.00
High: 294.00
Low: 294.00
Prev. Close: 298.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

14 Jul 2010 09:18

RNS Number : 3215P
Hutchison China Meditech Limited
14 July 2010
 



For filings with the FSA include the annex

For filings with issuer exclude the annex

 

TR-1: notification of major interests in shares i

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

HUTCHISON CHINA MEDITECH LTD

 

2. Reason for the notification (please tick the appropriate box or boxes) :

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to the notification obligation: iii

 

Slater Investments Ltd

 

4. Full name of shareholder(s)  (if different from

3.): iv

5. Date of the transaction and date on which the threshold is crossed or reached: v

 

12 July 2010

6. Date on which issuer notified:

 

13 July 2010

7. Threshold(s) that is/are crossed or reached: vi, vii

 

Over 7%

 

1.

1. 1. 1.

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of shares

 

if possible using the ISIN CODE

Situation previous to the triggering transaction

 

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

B11Y2X4

3,228,165

3,228,165

2,126,769

2,126,769

1,619,000

3.11%

4.11%

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date xiii

Exercise/ Conversion Period xiv

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date xvii

Exercise/ Conversion Period xviii

Number of voting rights instrument refers to

% of voting rights xix, xx

Nominal

Delta

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

3,745,769

7.24%

 

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

 

13. Additional information:

14. Contact name:

 

Nicola Smith

15. Contact telephone number:

 

+44 20 7330 6130

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUSAWRRNABARR
Date   Source Headline
26th Aug 20217:00 amRNSPhase Ib/II Trial of Fruquintinib & Tislelizumab
23rd Aug 20217:00 amRNSHUTCHMED Selected for Certain Hang Seng Indexes
17th Aug 20219:30 amRNSELECTRONIC COMMUNICATION OF CORPORATE INFORMATION
9th Aug 20217:00 amRNSHUTCHMED & Epizyme Announce TAZVERIK Collaboration
30th Jul 20219:30 amRNSTotal Voting Rights
28th Jul 202112:00 pmRNSInterim Results and Business Updates
28th Jul 20217:00 amRNSPhase II Trial of ORPATHYS Initiated
23rd Jul 202112:01 pmRNSStabilizing Actions & End of Stabilization Period
16th Jul 202110:50 amRNSHolding(s) in Company
16th Jul 20217:00 amRNSSurufatinib MAA Submitted and Validated by the EMA
14th Jul 20219:35 amRNSHolding(s) in Company
13th Jul 20217:00 amRNSFirst Commercial Sale of ORPATHYS® in China
12th Jul 20212:35 pmRNSFull Exercise of the Over-allotment Option
6th Jul 20219:30 amRNSHUTCHMED Initiates Phase I Trials of HMPL-295
2nd Jul 202111:15 amRNSHolding(s) in Company
2nd Jul 20219:30 amRNSNotice of Results
1st Jul 202111:00 amRNSUS FDA Accepts NDA Filing for Surufatinib
30th Jun 202110:02 amRNSHoldings in Company
30th Jun 202110:01 amRNSTotal Voting Rights
30th Jun 202110:00 amRNSClosing of Global Offering and Hong Kong Listing
29th Jun 20217:00 amRNSBlocklisting Six Monthly Return
23rd Jun 20213:21 pmRNSHUTCHMED Announces Pricing of Global Offering
22nd Jun 20216:22 pmRNSSavolitinib approved in China for lung cancer
18th Jun 20214:05 pmRNSHUTCHMED Announces NMPA Approval of Surufatinib
18th Jun 20217:01 amRNSHUTCHMED Launches Hong Kong IPO
18th Jun 20217:00 amRNSDisclosure Update
20th May 20217:00 amRNSClinical Data to be Presented at ASCO21
17th May 20217:00 amRNSHUTCHMED to Host Company Update
7th May 202112:00 pmRNSHUTCHMED to Attend Upcoming Investor Conferences
4th May 20218:00 amRNSChange of Company Name
4th May 20217:00 amRNSSurufatinib FDA Rolling NDA Submission Completed
30th Apr 20214:41 pmRNSSecond Price Monitoring Extn
30th Apr 20214:35 pmRNSPrice Monitoring Extension
29th Apr 20217:00 amRNSPhase II Registration Study of HMPL-689 Initiated
28th Apr 20212:20 pmRNSResult of AGM
23rd Apr 20217:00 amRNSVesting of awards under Long Term Incentive Plan
14th Apr 202110:30 amRNSNotification of Dilution of Voting Rights
8th Apr 20218:30 amRNS$100m Investment by Baring Private Equity Asia
31st Mar 20217:00 amRNSTotal Voting Rights
29th Mar 20219:30 amRNSGrant of LTIP Awards and Share Options
29th Mar 20217:00 amRNSInitiates International Phase I Trials of HMPL-306
26th Mar 20217:00 amRNSAnnual Financial Report
24th Mar 20211:30 pmRNSAgreement to Divest Non-Core OTC Joint Venture
24th Mar 20217:00 amRNSPhase Ib/II Trial of Surufatinib with Tislelizumab
10th Mar 20217:00 amRNSVesting of awards under Long Term Incentive Plan
4th Mar 20213:15 pmRNSPublication of Form 20-F
4th Mar 202112:00 pmRNSFinal Results, Business Update and Name Change
3rd Feb 20217:00 amRNSNotice of Results
14th Jan 202110:00 amRNSSavolitinib Data to be Presented at Virtual WCLC
11th Jan 20217:00 amRNSChi-Med & Inmagene Announce Strategic Partnership

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.